Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
B413378-1mg | 1mg | In stock | $23.90 | |
B413378-5mg | 5mg | In stock | $97.90 | |
B413378-10mg | 10mg | In stock | $162.90 | |
B413378-25mg | 25mg | In stock | $303.90 | |
B413378-50mg | 50mg | In stock | $489.90 | |
B413378-100mg | 100mg | In stock | $815.90 | |
B413378-250mg | 250mg | In stock | $1,836.90 |
Antiviral Inhibitors
Synonyms | F0001-1475 | S033188 | S-033188 | {[(3R)-2-[(2S)-12,13-difluoro-9-thiatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl]-9,12-dioxo-5-oxa-1,2,8-triazatricyclo[8.4.0.0^{3,8}]tetradeca-10,13-dien-11-yl]oxy}methyl methyl carbonate | baloxavir |
---|---|
Specifications & Purity | Moligand™, ≥97% |
Biochemical and Physiological Mechanisms | Baloxavir marboxil, a cap-endonuclease inhibitor, is an antiviral drug. |
Storage Temp | Store at -20°C,Argon charged |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Polymerase acidic protein inhibitor |
Product Description | Information Baloxavir marboxil Baloxavir marboxil, a cap-endonuclease inhibitor, is an antiviral drug. In vivo Single-dose oral baloxavir marboxil is well tolerated, had a favorable safety profile, and has favorable pharmacokinetic characteristics, including a long half-life, supporting single oral dosing. In nonclinical studies, baloxavir marboxil is a prodrug and is converted to an active form, baloxavir acid, by hydrolysis. After single oral administration in rats and monkeys, plasma concentrations of baloxavir marboxil are below the lower limit of quantification (LLOQ) at all sampling points, and area under the plasma concentration-time curve of baloxavir acid increased dose proportionally. The major excretion route of radioactivity is via fecal excretion, whereas urinary excretion was low in rats and monkeys. Baloxavir marboxil has shown therapeutic activity in preclinical models of influenza A and B virus infections, including strains resistant to current antiviral agents. In murine models of seasonal influenza and avian influenza A(H5N1) or A(H7N9), orally administered baloxavir is associated with rapid reductions in pulmonary viral loads and decreased mortality. |
ALogP | 2.602 |
---|---|
Rotatable Bond | 6 |
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | [(3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-9,12-dioxo-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-dien-11-yl]oxymethyl methyl carbonate |
---|---|
INCHI | InChI=1S/C27H23F2N3O7S/c1-36-27(35)39-14-38-25-19(33)8-9-31-24(25)26(34)30-10-11-37-12-21(30)32(31)23-15-6-7-18(28)22(29)17(15)13-40-20-5-3-2-4-16(20)23/h2-9,21,23H,10-14H2,1H3/t21-,23+/m1/s1 |
InChi Key | RZVPBGBYGMDSBG-GGAORHGYSA-N |
Canonical SMILES | COC(=O)OCOC1=C2C(=O)N3CCOCC3N(N2C=CC1=O)C4C5=C(CSC6=CC=CC=C46)C(=C(C=C5)F)F |
Isomeric SMILES | COC(=O)OCOC1=C2C(=O)N3CCOC[C@H]3N(N2C=CC1=O)[C@H]4C5=C(CSC6=CC=CC=C46)C(=C(C=C5)F)F |
PubChem CID | 124081896 |
Molecular Weight | 571.55 |
PubChem CID | 124081896 |
---|---|
CAS Registry No. | 1985606-14-1 |
ChEMBL Ligand | CHEMBL4297503 |
DrugBank Ligand | DB13997 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
H2219082 | Certificate of Analysis | Jun 18, 2022 | B413378 |
H2219083 | Certificate of Analysis | Jun 18, 2022 | B413378 |
H2219084 | Certificate of Analysis | Jun 18, 2022 | B413378 |
H2219087 | Certificate of Analysis | Jun 18, 2022 | B413378 |
H2219088 | Certificate of Analysis | Jun 18, 2022 | B413378 |
H2219089 | Certificate of Analysis | Jun 18, 2022 | B413378 |
H2219090 | Certificate of Analysis | Jun 18, 2022 | B413378 |
Solubility | Solubility (25°C) In vitro DMSO: 100 mg/mL (174.96 mM); Ethanol: 7 mg/mL (12.24 mM); Water: Insoluble; |
---|---|
DMSO(mg / mL) Max Solubility | 100 |
DMSO(mM) Max Solubility | 174.962820400665 |
Water(mg / mL) Max Solubility | <1 |
Pictogram(s) | GHS09 |
---|---|
Hazard Statements | H411:Toxic to aquatic life with long lasting effects |
Precautionary Statements | P273:Avoid release to the environment. P501:Dispose of contents/container to ... P391:Collect spillage. |
1. Ivashchenko AA, Mitkin OD, Jones JC, Nikitin AV, Koryakova AG, Ryakhovskiy A, Karapetian RN, Kravchenko DV, Aladinskiy V, Leneva IA et al.. (2020) Non-rigid Diarylmethyl Analogs of Baloxavir as Cap-Dependent Endonuclease Inhibitors of Influenza Viruses.. J Med Chem, 63 (17): (9403-9420). [PMID:32787099] [10.1021/op500134e] |
2. Takashita E, Morita H, Ogawa R, Nakamura K, Fujisaki S, Shirakura M, Kuwahara T, Kishida N, Watanabe S, Odagiri T. (2018) Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil.. Front Microbiol, 9 (13): (3026). [PMID:30574137] [10.1021/op500134e] |
3. Abraham GM, Morton JB, Saravolatz LD. (2020) Baloxavir: A Novel Antiviral Agent in the Treatment of Influenza.. Clin Infect Dis, 71 (7): (1790-1794). [PMID:32020174] [10.1021/op500134e] |